2023 Annual Report - Growing Community

GROWING

COMMUNITY 2023 ANNUAL REPORT

TABLE OF

CONTENTS

2

8

GROWING COMMUNITY THROUGH

RESEARCH

12

GROWING COMMUNITY THROUGH

SCIENTIFIC PROGRAMS

14 16 18 20 22

GROWING COMMUNITY THROUGH

EVENTS

GROWING COMMUNITY THROUGH

FUNDRAISING

GROWING COMMUNITY THROUGH

SUPPORT SERVICES FINANCIALS

GROWING COMMUNITY THROUGH

OUR DONORS

LYMPHOMA RESEARCH FOUNDATION | 2023 ANNUAL REPORT

As we reflect on 2023, we see a year in which the Foundation was able to make new connections, grow our community, and expand the impact of our mission and the reach of our work.

4

LETTER FROM THE

CEO & CHAIR OF THE BOARD

Meghan Gutierrez Chief Executive Officer

Dear Friends, very year, we are humbled to highlight the growth E

and incredible progress made by the Lymphoma Research Foundation (LRF), which is made possible through your generosity and commitment to our mission to eradicate lymphoma and serve those touched by this disease.

As we reflect on 2023, we see a year in which the Foundation was able to make new connections, grow our community, and expand the impact of our mission and reach of our work. We were able to convene many of our in-person patient and professional programs for the first time in three years and expand our online offerings for patients as well. Being back in person for events like Partners In Hope allowed devoted partners like Liam Hendriks of the Chicago White Sox and his wife, Kristi, to join us and tell their story. Our Annual Gala raised over a million dollars for our mission and was globally supported by our devoted partners and industry leaders. New friends, like TikTok star Anthony Corrado, joined us for our Chicago Walk, encouraging others to join our journey and efforts. Our hybrid education programs ensured that thousands of patients and their families could access expert information and support in whichever way made them comfortable. We also continued to grow online and through services like the LRF Helpline, serving more than 10,000 patients and caregivers last year alone.

Steven Eichberg Chair, Board of Directors

The Foundation continues to fund a robust portfolio of cutting-edge research across every lymphoma subtype, and in 2023, LRF funded 27 research grants totaling nearly $6 million. This year’s report details our many grantees and the critical projects that would not be possible without your continued generous support.

In partnership with our expert Scientific Advisory Board, the Foundation was also able to harness its convening power to address important areas of unmet need. In 2023, LRF explored two of these critical areas: Mantle Cell Lymphoma (MCL) and Minimum Residual Disease (MRD). LRF also officially ratified the charter of its global Adolescent and Young Adult (AYA) Lymphoma Consortium, a first-of-its-kind effort aimed at bridging the gap in care that is experienced by this underserved patient population, as we continue to lead the way in the investigation of those lymphomas that disproportionately impact young people. LRF also began a new effort focused on the unique and understudied needs of lymphoma and CLL survivors, meeting an unmet need that will grow in the years ahead.

While much work remains, your partnership and dedication propel us forward each and every day. We remain as dedicated as ever to our shared goals and service to the more than 1 million Americans living with and surviving lymphoma.

Growing together,

Steven Eichberg Chair, Board of Directors

Meghan Gutierrez Chief Executive Officer

LYMPHOMA RESEARCH FOUNDATION | 2023 ANNUAL REPORT

GROWING COMMUNITY THROUGH OUR

BOARD OF DIRECTORS FY 2023 MEMBERSHIP

STEVEN EICHBERG Chair Plymouth, MA JEFF BLOCK Vice Chair and Treasurer San Francisco, CA

BOB MCAULEY Charlottesville, VA

MEMBERS EMERITUS

JOHN A. NELSON Bridgehampton, NY

New York, NY

MORTON COLEMAN, MD

SCOTT PANSKY Tarzana, CA

BARBARA FREUNDLICH Founder New York, NY

DIANE PARKS Carbondale, CO

TOM GOLDSTONE New York, NY

JOEL POLLICK Brooklyn, NY

DONNA REINBOLT Houston, TX

MICHAEL AKINYELE Upper Marlboro, MD

STEVEN J. PRINCE Past Chair Purchase, NY

ROBERT WERNER Aventura, FL

MICHAEL FROY Chicago, IL

KEVIN SHEA Naples, FL

HARRIET GREENBERG New York, NY

SONALI M. SMITH, MD, FASCO Chair, Scientific Advisory Board Chicago, IL

KIM METCALF Vice Chair Landenberg, PA LEIGH OLSON Secretary Miami Beach, FL

JOHN LEONARD, MD Past Chair, Scientific Advisory Board New York, NY

MICHAEL WERNER Immediate Past Chair Chicago, IL

GROWING COMMUNITY THROUGH OUR

CEO ADVISORY COUNCIL FY 2023 MEMBERSHIP

MARTHA CRAWFORD Santa Fe, NM

KATHRYN MCGILL Dallas, TX

LYNDSAY SPRINGER Washington, DC

AMY KIMBALL Easton, MD

JACKIE QUAN Washington, DC

GARY TURKISH Hilton Head, SC

LEWIS KWEIT Long Island, NY

ADWIN SPRINGER London, Ontario, Canada

6

GROWING COMMUNITY THROUGH OUR

SCIENTIFIC ADVISORY BOARD FY 2023 MEMBERSHIP

SONALI M. SMITH, MD, FASCO

Chair The University of Chicago

ANN S. LACASCE, MD, MMSc

LEO I. GORDON, MD, FACP

Institute for Cancer Genetics, Columbia University

MICHAEL GREEN, PhD

Columbia University H. Irving Comprehensive Cancer Center

Chair-Elect Harvard Medical School Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

RANJANA ADVANI, MD

THOMAS M. HABERMANN, MD

Stanford University School of Medicine

ASH A. ALIZADEH, MD, PhD Stanford University School of Medicine

STEPHEN ANSELL, MD, PhD Mayo Clinic, Rochester

KRISTIE A. BLUM, MD Winship Cancer Institute of Emory University

JENNIFER BROWN, MD

LISA RIMSZA, MD

Past Chair, 2017-2019 Mayo Clinic, Rochester

LISA GIULINO ROTH, MD Weill Cornell Medicine

STEVEN M. HORWITZ, MD Memorial Sloan Kettering Cancer Center

ERIC D. HSI, MD

BC Cancer, Vancouver

BRAD S. KAHL, MD Washington University School of Medicine

KARA KELLY, MD

JAMES CERHAN, MD, PhD ETHEL CESARMAN, MD, PhD

BRUCE D. CHESON, MD, FACP, FAAAS, FASCO

CHRISTIAN STEIDL, MD BC Cancer, Vancouver

BRIAN K. LINK, MD

JOHN M. TIMMERMAN, MD

SANDEEP DAVE, MD, MS

University of Miami Health System Sylvester Comprehensive Cancer Center

UCLA Jonsson Comprehensive Cancer Center

IZIDORE S. LOSSOS, MD

PETER MARTIN, MD

MARGARET SHIPP, MD Harvard Medical School Dana-Farber Cancer Institute Tampa General Hospital

University of Iowa

KIERON M. DUNLEAVY, MD

LAURIE SEHN, MD, MPH BC Cancer, Vancouver

EDUARDO M. SOTOMAYOR, MD

JOHN P. LEONARD, MD

Past Chair, 2012-2015 NewYork-Presbyterian Hospital Weill Cornell Medicine

Past Chair, 2010-2012 The Center for Cancer and Blood Disorders Duke University

KERRY J. SAVAGE, MD BC Cancer, Vancouver

DAVID W. SCOTT, MBChB, PhD

Wake Forest

Roswell Park Comprehensive Cancer Center University at Buffalo Jacobs School of Medicine and Biomedical Sciences

NewYork-Presbyterian Hospital Weill Cornell Medicine

BARBARA PRO, MD

Mayo Clinic, Arizona

Dana-Farber Cancer Institute Mayo Clinic, Rochester

LAURA PASQUALUCCI, MD

Past Chair, 2015-2017 Robert H. Lurie Comprehensive Cancer Center of Northwestern University

SVEN de VOS, MD, PhD UCLA Jonsson Comprehensive Cancer Center

HANS-GUIDO WENDEL, MD Memorial Sloan Kettering Cancer Center

Georgetown Lombardi Comprehensive Cancer Center

Weill Cornell Medicine

KOJO S.J. ELENITOBA-JOHNSON, MD

NewYork-Presbyterian Hospital Weill Cornell Medicine

Immediate Past Chair, 2019-2021 Memorial Sloan Kettering Cancer Center

LINDSAY MORTON, PhD

MEMBERS EMERITUS

Memorial Sloan Kettering Cancer Center

ANDREW M. EVENS, DO, MSc, FACP Rutgers Cancer Institute of New Jersey

CHRISTOPHER R. FLOWERS, MD, MS The University of Texas MD Anderson Cancer Center

JONATHAN W. FRIEDBERG, MD, MMSc University of Rochester James P. Wilmot Cancer Institute

ARI MELNICK, MD

ANDREW D. ZELENETZ, MD, PhD

National Cancer Institute

MORTON COLEMAN, MD

LORETTA NASTOUPIL, MD

NewYork-Presbyterian Hospital Weill Cornell Medicine

The University of Texas MD Anderson Cancer Center

TERESA PALOMERO, PhD Institute for Cancer Genetics, Columbia University

KANTI R. RAI, MD Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

MICHAEL E. WILLIAMS, MD, ScM University of Virginia Cancer Center

LYMPHOMA RESEARCH FOUNDATION | 2023 ANNUAL REPORT

GROWING COMMUNITY THROUGH

RESEARCH In April, the Lymphoma Research Foundation (LRF) announced its 2023 grant class — 27 research grants awarded to scientists based at many of the world’s leading cancer research institutions — totaling more than $5.4 million in innovative lymphoma and chronic lymphocytic leukemia (CLL) research.

LRF maintains a strong commitment to supporting early-career investigators, ensuring they can build a successful career in the field of lymphoma research. This commitment is illustrated by the 16 grants awarded to early-career investigators this year. They include four dynamic Clinical Investigator Career Development Awards (CDA), which support physician investigators at the level of advanced fellow or junior faculty member who will contribute to the development of new lymphoma therapies and diagnostic tools. Also included are seven Postdoctoral Fellowship Grants, designed to support investigators at the level of advanced fellow or postdoctoral researcher in laboratory or clinic-based research with results and conclusions that must be relevant to the treatment, diagnosis, or prevention of lymphoma.

CLINICAL CAREER DEVELOPMENT AWARD (CDA) ELISE CHONG, MD Health Equity Initiative & LRF’s 500th Grantee UNIVERSITY OF PENNSYLVANIA, PERELMAN SCHOOL OF MEDICINE

PATRIZIA MONDELLO, MD, PHD MAYO CLINIC, ROCHESTER

8

RONI SHOUVAL, MD, PHD MEMORIAL SLOAN KETTERING CANCER CENTER

XIAOLONG (ALAN) ZHOU, MD NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE

FOLLICULAR LYMPHOMA PRIORITY RESEARCH GRANT Also this year, LRF funded five Follicular Lymphoma Priority Research grants as part of the Jamie Peykoff Follicular Lymphoma Initiative. Established in 2020 through the generosity of the Peykoff family and The Institute for Follicular Lymphoma, the $10 million Initiative is poised to transform the follicular lymphoma (FL) treatment landscape for tens of thousands of patients by harnessing the Foundation’s unique resources, convening the world’s experts in FL research and patient care, and driving direct investment in clinical research.

ARASH ALIZADEH, MD, PHD Peykoff Initiative Investigator STANFORD UNIVERSITY

WENDY BÉGUELIN, PHD Peykoff Initiative Investigator WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY

JOSHUA BRODY, MD Peykoff Initiative Investigator ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

“My goal is to maintain a strong connection to patient care, bringing the latest advancements in research directly to those who stand to benefit from them.”

ROBERT KRIDEL, MD, MPH, PHD Peykoff Initiative Investigator UNIVERSITY HEALTH NETWORK, TORONTO

Roni Shouval, MD, PhD MATTHEW MAURER, D.M.SC Peykoff Initiative Investigator MAYO CLINIC, ROCHESTER

LYMPHOMA RESEARCH FOUNDATION | 2023 ANNUAL REPORT

POSTDOCTORAL FELLOWSHIP GRANT EDWARD DOMINGUEZ, PHD Health Equity Initiative BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE

TAYLA HEAVICAN-FORAL, PHD Health Equity Initiative & Dr. Oliver Press Memorial Fellow DANA-FARBER CANCER INSTITUTE

ANOUCHKA LAURENT, PHD COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

YIFEI LIAO, PHD BRIGHAM AND WOMEN’S HOSPITAL

CHRISTOPHER SAUTER, MD PERELMAN SCHOOL OF MEDICINE, UNIVERSITY OF PENNSYLVANIA

SANKET SHAH, PHD Dr. Bruce D. Cheson Fellow WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY

“I was drawn to lymphoma research because it represents the forefront of translating scientific knowledge into actionable therapies for patients.”

Christopher Sauter, MD

AJLAN AL ZAKI, MD, PHD THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

10

LYMPHOMA SCIENTIFIC RESEARCH MENTORING PROGRAM:

CLINICAL SCHOLARS AYUSHI CHAUHAN, MD Gregory Scholar AUGUSTA UNIVERSITY

DANIEL ERMANN, MD UNIVERSITY OF UTAH

ERIKA HAYDU, MD, PHD Runge Scholar MASSACHUSETTS GENERAL HOSPITAL

SWETHA KAMBHAMPATI, MD CITY OF HOPE

CHRISTINE RYAN, MD Rai Scholar DANA-FARBER CANCER INSTITUTE

TIMOTHY VOORHEES, MD OHIO STATE UNIVERSITY

LYMPHOMA SCIENTIFIC RESEARCH MENTORING PROGRAM:

LAB/TRANSLATIONAL SCHOLARS ALEXANDER BOARDMAN, MD Dobosh Family Scholar MEMORIAL SLOAN KETTERING

ANDREW JALLOUK, MD, PHD MD ANDERSON CANCER CENTER

ERIN PARRY MD, PHD DANA-FARBER CANCER INSTITUTE

AJLAN AL ZAKI, MD, PHD MD ANDERSON CANCER CENTER

WEN-HSUAN WENDY LIN, MD, PHD COLUMBIA UNIVERSITY

LYMPHOMA RESEARCH FOUNDATION | 2023 ANNUAL REPORT

GROWING COMMUNITY THROUGH

SCIENTIFIC PROGRAMS Facilitating collaboration and partnerships among academic scientists, clinicians, government, regulatory agencies, and patients is a critical component of the Foundation’s work. Through its global lymphoma consortia, research initiatives, and scientific workshops, the Lymphoma Research Foundation (LRF) mobilizes the research community to overcome systemic challenges and expedite the development of treatments. In 2023, LRF used its convening power to explore two important areas of scientific discovery and unmet need: mantle cell lymphoma (MCL) and Minimum Residual Disease (MRD).

12

Mantle Cell Lymphoma (MCL) Mantle cell lymphoma (MCL) is a rare, typically aggressive form of non-Hodgkin lymphoma (NHL) that accounts for roughly 6% of all NHL cases in the United States. Recognizing that a targeted research focus on MCL would benefit this underserved and understudied patient population, the Lymphoma Research Foundation (LRF) began awarding MCL-specific research grants and gathering its MCL grantees for a regular scientific meeting to report on their findings and form collaborations.

Twenty years since the Workshop’s initial establishment, LRF hosted an MCL Scientific Workshop in May 2023 chaired by LRF Scientific Advisory Board Member Dr. Eduardo Sotomayor, MD (Tampa General Hospital Cancer Institute). The program also included a keynote speech from world-leading MCL expert Elias Campo, MD, PhD (Institut d’Investigacions Biomèdiques August Pi i Sunyer), who was honored with LRF’s Leadership Award for his contributions to the field of MCL research. Dr. Campo and Dr. Sotomayor shared more about this year’s meeting and what the future of MCL research holds.

Minimum Residual Disease (MRD) Minimal residual disease (MRD) is the persistence or reemergence of detectable tumor cells after cancer treatment. A quantitative definition, however, remains elusive, as more effective therapies have increasingly reduced tumor burden, while increasingly sensitive MRD tests have enabled lower and lower thresholds of detection. It is now widely agreed that MRD has prognostic value, but optimal application in clinical and research settings remains unclear, largely due to broad heterogeneity between trial designs, patient populations, therapeutic regimens, and disease subtypes. This latter variable is particularly relevant in lymphoma, as subtypes of disease present diverse biological characteristics that may impact the utility of MRD testing. At the Lymphoma Research Foundation’s inaugural 2023 MRD and Lymphoma Scientific Symposium, experts convened to discuss the state of MRD science and technology, current research findings and possible treatment implications, the emerging role of MRD in clinical trial design, regulatory considerations, pharmaceutical industry perspectives, current gaps, future directions, and next steps.

LYMPHOMA RESEARCH FOUNDATION | 2023 ANNUAL REPORT

GROWING COMMUNITY THROUGH

EVENTS

Lymphoma Research Foundation (LRF) provides opportunities for members of the lymphoma community and their friends to support innovative research and patient care by attending and sponsoring unique events across the country. Here are just a few examples of events that propelled LRF’s work in 2023.

Partners In Hope Chicago Raises More Than $110,000 On June 1, over 200 attendees gathered in Chicago for the inaugural Partners In Hope: A Scientific Social event, chaired

by Kristi Hendriks, wife of lymphoma survivor and Chicago White Sox player Liam Hendriks. This evening honored longtime Lymphoma Research Foundation (LRF) Scientific Advisory Board member Dr. Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for his decades of commitment and care to his patients and his pioneering work that has changed the landscape of lymphoma research.

Guests enjoyed a world-class wine tasting and raised more than $110,000 in support of critical lymphoma research on this special night.

14

Close Out Cancer Throughout the 2023 Major League Baseball season, LRF was fortunate to team up the Chicago White Sox and Liam and Kristi Hendriks to create special “Close Out Cancer” T-shirts sold to supporting fans of the Sox and Hendriks in his lymphoma treatment. The proceeds of this one-of-a-kind campaign raised over $130,000 throughout the 2023 Sox season for LRF’s Patient Aid Grant program.

Golf Invitationals Raise More Than $350,000 LRF supporters gathered on April 28 for the inaugural DC Metro Area Golf Outing, hosted at the Links at Challedon in Mount Airy, Maryland, one of the area’s premier golf courses. Former Washington football great Mark Rypien joined the golfers as they hit the links, raising over $50,000 in critical funds supporting LRF’s community of patients, survivors, researchers, and caregivers. The following month, LRF donors and supporters teed off at Quaker Ridge Golf Club in Scarsdale, New York, on May 23 for the 11th Annual LRF Golf Invitational. Golfers tested their skills on one of the most prestigious golf courses in the country and raised $300,000 to further LRF’s mission of eradicating lymphoma. The event, founded and chaired by Steve Prince and Jim Stern, has raised more than $3,000,000 since its inception.

LRF Annual Gala Raises More Than $1M Hope means something different to everyone: a promising new treatment, a breakthrough in research, a lifeline during a difficult moment, and the promise of brighter days ahead. The LRF Annual Gala this year celebrated these Stories of Hope from across the lymphoma community at the Ziegfeld Ballroom in New York City on September 28. This year’s event honored Kara M. Kelly, MD, of Roswell Park Comprehensive Cancer Center with the Distinguished Leadership Award and Genmab with the Corporate Leadership Award in recognition of their commitment to serving the lymphoma community and advancing cures. This year’s event, which featured an exciting live auction, a rousing Raise it For LRF segment, and the inaugural Emerging Philanthropists After-Party, raised over $1.1M in support of LRF’s mission.

GROWING COMMUNITY THROUGH

FUNDRAISING Thousands of people across the country turn their talents and interests into unique fundraising events to support the Lymphoma Research Foundation (LRF) mission. Whether they attended a Lymphoma Walk, participated in a marathon or road race, or created a new event, LRF’s partners, generous donors, and volunteers are all part of our growing community and helped to make 2023 one of the best years ever!

LA Marathon and NY Marathon Team LRF took to the streets of Los Angeles alongside over 20,000 fellow racers for the 38th annual Los Angeles Marathon on March 19, 2023. The team of three dedicated runners raised $10,000 to power lymphoma research and to raise awareness for LRF’s mission as they ran 26.2 miles, starting at Dodger Stadium in downtown LA and crossing the finish line in Century City. Ten runners represented LRF at the NYC Marathon, raising $25,000 for lymphoma research and support services.

16

Fundraise Your Way Awards On March 14, 2023, LRF staff and supporters joined together to celebrate its dedicated Fundraise Your Way volunteers during the inaugural Fundraise Your Way Awards. Volunteers across the country who turned their talents and interests into unique fundraising events were honored in categories including Rookie of the Year, Most Innovative Fundraiser, Ride Team of the Year, Walk Team of the Year, and Endurance Athlete of the Year.

LRF Inaugural Giving Day Each year, September 15 marks World Lymphoma Awareness Day, with a number of buildings and landmarks across the globe lighting up red to spread lymphoma awareness worldwide. This year, September 15 held even more special significance as we marked it the inaugural LRF Giving Day: a celebration of all that we make possible together in our support of lymphoma patients and critical blood cancer research. Together, the lymphoma community raised over $32,000 on LRF Giving Day 2023 to power the next generation of lymphoma research and to give hope to patients in need.

Mattress Firm LRF was proud to partner once again with our friends at Mattress Firm for a special campaign held October 18-31 that allowed customers the option to donate to the Foundation at the register.

This campaign raised nearly $12,000 in just two weeks.

Tony Corrado and The Chicago Lymphoma Walk In July 2023, Corrado joined the Lymphoma Research Foundation at its Chicago Lymphoma Walk and raised more than $25,000 within just a few weeks. Over 100 people came to the event as part of Corrado’s team, traveling from as far as Indiana, Wisconsin, and New York.

Relaunch of the Research Ride at the Comus Inn Ninety riders took to the back roads of Montgomery County, Maryland, on Sunday, October 1, as they cycled to raise critical funds to power LRF’s research programs. The event kicked off at the foot of Sugarloaf Mountain and featured both 25- and 50-mile rides through beautiful landscapes offering panoramic views. Afterward, cyclists toasted their successes at an after-party held at the historic Comus Inn, celebrating the more than $105,000 they raised to fund the future of lymphoma research.

GROWING COMMUNITY THROUGH

SUPPORT SERVICES

A diagnosis of lymphoma or chronic lymphocytic leukemia (CLL) can bring about many different emotions and numerous questions, whether you are newly diagnosed or seeking help with long-term survivorship. The Foundation offers a wide range of support services for people with lymphoma and their loved ones through the Lymphoma Research Foundation (LRF) Helpline. In 2023, trained Helpline staff provided individualized information on types of lymphoma, diagnostic tests, treatment options, potential side effects, and the latest in research to more than 10,000 patients and caregivers.

18

Contact the LRF Helpline toll-free at (800) 500-9976 or via email at helpline@lymphoma.org with any of your lymphoma-related questions, Monday–Friday, 9:30 a.m.–7:30 p.m.

Eastern Standard Time (EST).

LRF Helpline Throughout the past year and the entire pandemic, Helpline staff members provided a range of free services, including providing patients and caregivers with a list of questions to ask their healthcare team and conducting customized clinical trial searches through the LRF Clinical Trials Information Service.

Through the Lymphoma Support Network, which has a membership of over 7,000, both patients and caregivers were connected with others who have gone through a similar experience. Patients and caregivers were also connected with financial assistance resources and other referrals for existing unmet medical and financial needs.

Focus on Lymphoma Mobile App Mobile health technology is becoming an increasingly popular way to empower patients to take charge of their health by offering an easy way to track symptoms, record appointments, log lab results, and access educational resources. LRF has been leading the way in mobile health technology since the launch of its first-of-its-kind mobile app, Focus on Lymphoma, in 2013. The award-winning app was designed to help patients and caregivers better understand and manage their disease through comprehensive information tailored to the user’s specific lymphoma subtype. It provides tools to help users record/take notes during doctor sessions and track medications, blood results, and symptoms. Building upon the success of Focus on Lymphoma, LRF updated its app this year with several quality-of-life improvements based on user feedback to continue providing these important tools in the best possible way to lymphoma patients and their caregivers.

LYMPHOMA RESEARCH FOUNDATION | 2023 ANNUAL REPORT

FINANCIALS

FOR THE FISCAL YEAR ENDING JUNE 30, 2023

REVENUES

PROGRAM SERVICES EXPENSES

EXPENSES

Contributions and grants

$14.8 million [85%]

Special events and revenue

$2.3 million [13%]

Investment income and other income

$0.4 million [2%]

Research

$7.0 million [63%]

Education programs and patient services

$3.1 million [28%]

Communications and advocacy

$1.1 million [9%]

Program services

$11.2 million [76%]

Fundraising

$2.1 million [14%]

Administration

$1.4 million [10%]

The Condensed Balance Sheets and Statements of Activities of the Lymphoma Research Foundation as of June 30, 2023, and 2022 have been derived from Lymphoma Research Foundation’s audited financial statements. The Lymphoma Research Foundation’s complete set of audited financial statements and related information can be found on the Lymphoma Research Foundation’s website, lymphoma.org. The Financial Statements have been audited by BDO.

20

FINANCIAL REPORT

(IN THOUSANDS) AS OF JUNE 30, 2023 ASSETS

2023

LIABILITIES & NET ASSETS

12,238

Research grants payable

Investments

23,767

Refundable advances

Contributions and grants receivable

3,223

Accounts payable and accrued expenses

Prepaid expenses and other assets

1,834

Accrued salaries and vacation

41,062

TOTAL LIABILITIES

$

10,723

Unrestricted net assets

$

5,181

Cash and cash equivalents

TOTAL ASSETS

$

$

2023 $

8,552 125 1,742 304

Temporarily restricted net assets

25,158

TOTAL NET ASSETS

$

30,339

TOTAL LIABILITIES & NET ASSETS

$

41,062

CONDENSED STATEMENT OF ACTIVITIES

(IN THOUSANDS) AS OF JUNE 30, 2023 CONTRIBUTIONS & REVENUES Special events revenues & contributions

2023 $

Investments & other income Contributions & revenues TOTAL CONTRIBUTIONS & REVENUES

2,164

Program services

493

Supporting services

14,850 $

17,507

$

11,180 3,544

TOTAL EXPENSES

$

14,724

INCREASE IN UNRESTRICTED NET ASSETS

$

-534

INCREASE IN TEMPORARY RESTRICTED NET ASSETS

$

3,317

INCREASE IN NET ASSETS

$

2,783

LYMPHOMA RESEARCH FOUNDATION | 2023 ANNUAL REPORT

GROWING COMMUNITY THROUGH

OUR DONORS The progress made by the Lymphoma Research Foundation in 2023 was made possible by its many supporters — patients, survivors, caregivers, family members, scientists, clinicians, nurses, communities, and companies — who recognize that partnership is critical to advancing innovative lymphoma research and the development of essential patient education programs.

LEADERSHIP DONORS Thank you to our leadership donors for providing hope to the lymphoma community through their commitment to supporting innovative research and evidence-based educational resources.

2seventy bio

Bristol-Myers Squibb

Lawrence D. & Gail Dobosh

AbbVie Inc.

Robert & Arlette Britton

Jean & Steven Eichberg

Acrotech Biopharma, LLC

The Bruning Foundation

Eli Lilly & Company

Annette & Jeff Adams

BTG International Inc.

Estate of Elvira Esterhazy

Adaptive Biotechnologies

Bruce & Christine Cheson

Robert & Amy Feilbogen

ADC Therapeutics

Chicago White Sox Charities

Norman J. & Doris Fisher Foundation

Walter J. Andrews

The Children’s Hospital of Buffalo Foundation

Richard I. Fisher

AstraZeneca Pharmaceuticals, LP

Estate of Christ H. Christensen

The David R. & Patricia D. Atkinson Foundation

Coghill Family Foundation

Gerald and Roberta Franklin Charitable Foundation

Michael & Patty Cohen

Barbara & Jerry Freundlich

Glenn R. August

Stacey Cohen

Frist Foundation

John & Caroline Ballantine

Morton & Joyce Coleman

Michael & Lynn Froy

Baranay Family Foundation

Susan & James Colletti

Bhargava & Harika Gannavarapu

Michael & Lana Beaury

Gladys Cook

Gantcher Family Foundation

BeiGene USA, Inc.

Deborah Sue Coppola

Robert & Linda Gardner

Steven & Jennifer Benenson

CRISPR Therapeutics, Inc.

Diane E. Geise

Maxa Schutzbank Berid

Joseph O. Cunningham, Jr.

Genentech

Cathy S. Bernard

Linda Cutter

Genmab US, Inc.

James Bisetti

Daiichi Sankyo, Inc.

Gary & Lori Gertzog

Gary L. Blackwell

Gary & Ellen Davis

Margie A. Gey

Jeffrey A. Block

Jane C. Davis

Tom & Jenn Goldstone

The Boyd Charitable Donation Fund

Laura De Reitzes

The Lillian & Larry Goodman Foundations

Aronow Foundation

22

Foundation Medicine, Inc.

Andre Goy

Bruce & Phipps Menk

Mona Sarnoff

Grassfield High School

Merck & Co., Inc.

Norton & Elaine Sarnoff

Scott & Harriet Greenberg

David & Barbara Messer

Roberta Sarnoff

Thomas & Mary Jo Habermann

Miltenyi Biomedicine

SBB Research Group Foundation

Estate of Irving Hammer

MorphoSys US Inc.

Daniel & Kiki Schneider

Richard & Tracy Hazan

Eugene & Mary Murphy

Seagen

Edward D. Heffner

John Nelson

Secura Bio

Kristi & Liam Hendriks

The Jerome and Elaine Nerenberg Foundation

Lance Shackway

Liza Newman

Paul & Joanne Simoneau

The Dubose & Dorothy Heward Memorial Foundation

Kevin & Kimberly Shea

Helen Hidley

The William and Anita Newman Foundation

Gary & Diane Hirsch

Rose Novak

Steven Hoffman

Novartis Pharmaceuticals Corp.

IFLI

Nurix Therapeutics, Inc.

Incyte Corporation

Morris W. Offit

The John & Louise Steegstra Memorial Fund

Ipsen Biopharmaceuticals, Inc.

Leigh & Cory Olson

Jane & James A. Stern

Jazz Pharmaceuticals, Inc.

ONO Pharma

W. Clement and Jessie V. Stone Foundation

Johnson & Johnson Family Companies

Otto-Whalley Family Foundation

David Stump

Katherine Johnson

Diane & Tim Parks

Mayo & Elizabeth Stuntz

Stephanie Johnson

Party for a Lifetime

Madhvi & Ramesh Subrahmanian

The Karches Foundation

Joseph E. Parzick

Susan & Jeffrey Sussman

Barrie & Glen Kassan

The Paul Foundation

Jim & Mary Taglia

Richard & Suzanne Kayne

Anne & Steve Pellegrini

Joshua & Kimara Targoff

John Keating

Pfizer

Lisa A. Taverna

James P. Kelly

David & Miriam Phalen & The Grinberg Family Foundation

Laura Tepper Diane & Gaylord Thormodsgard

Kite Pharma Inc.

Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered

by Janssen Scientific Affairs, LLC

William & Carolyn Klein

Pisani Family Foundation

Thomas N. Tryforos

Jahanna & Thomas Knight

Andrew & Andrea Potash

Ann Tunney

Leslie and Robert Kramig

The Prince Family Foundation

Phil Variano

Andrew & Elizabeth Kriegman

Matthew Prince

Byron & Laurie Vielehr

Andrew & Mara Kupferberg

Steven & Debra Prince

Anthony Volpe

Kyowa Kirin, Inc.

Robert & Tracey Pruzan

Michael & Laura Werner

Sidney & Ruth Lapidus

Anthony Ragucci

Scot & Yumiko Larsen

Regeneron Pharmaceuticals, Inc.

Richard L. & Lois S. Werner Family Foundation

Lehigh Chapter Of The Delta Chi Fraternity

Donna & Paul Reinbolt

Barry & Ilyse Leibowitz

Donna Riley

Le-Vel Brands, LLC.

Steven & Stephanie Rosen

Michael & Carolyn Levine

Lois & Jerry Rosenblum

Sandra Lundquist

Michele K. Ross

Paul V. Majkowski, Esq. Mallinckrodt Pharmaceuticals

Roswell Park Comprehensive Cancer Center

Billi & Bernard Marcus

Eric & Laurie Roth

Elizabeth Winslow

Carrie Marriott

Anne & David Rubin

Penny D. Wolf

Mel and Nora Masuda

Robert M. Rubin

Yablans Family Foundation

Edward E. Matthews

Rutgers, The State University of New Jersey

Andrea & Bruce Yablon

Roy Ryan

Adelaide W. Zabriskie Fund

Gregory E. Sacco, Jr.

Kurt & Denise Zumwalt

Kara Kelly Lawrence Kestin

Mattress Firm, Inc. Robert & Laura McAuley MEI Pharma, Inc. Thomas G. Mendell Eric & Debbi Mendelson

Michael & Carey Skinner Starwood Property Trust Jeffrey Stedman

Ira & Nan Theodore Shawn & Richard Tomasello

Robert Werner Bruce W. Wetzel Judy Whalley Donald & Virginia Whinfrey Sharon Wickes Michael & Rebecca Williams Suzanne Williams

The Richard H. Yearick Foundation

Sanofi U.S. Brad & Lesley Sarnoff

LYMPHOMA RESEARCH FOUNDATION | 2023 ANNUAL REPORT

CIRCLE OF HOPE

Thank you to our Circle of Hope partners, whose monthly support ensures we can respond to the needs of our community and invest in further groundbreaking research year-round.

Ileen Akers

Douglas Fairbanks

Aaron Krause

Joel Pollick & Emily Franklin

Jason Albano

Frank C. Famiano

Brian Kutschke

Erin Poole & David Gooch

Keith Alsberg

Richard & Lynne Feinstein

Label LLC

William M. Popper

Gary S. Anthony

Dennis & Debbie Ferguson

Desiree Lamonico

Arthur & Deborah Price

Angela M. Baglione

Theresa Fillinger

Richard & Michelle Lebreux

Angela Reel

Kathryn Baine

Yury Flom

Erica Lecce

James E. Rodgers

Micah Banner

Thomas J. Forbes

Brandon Lespron

Lauren Roland

Kaethe Bierbach

Juliana Fuller

Elizabeth Lesser

Kevin Rosier

Tony Blanco

Patricia Gandy

Casey Lipscomb

Rebecca Russell

Christine M. Bolanis

Cynthia Gargagliano

Natasha Llewellyn

Mark Salandra

Dana Bork

Margaret A. Ghering

Larry Loose

Lawrence Simon

Barbara G. Bornstein

John Greabe & Martha Madsen

Ira & Lois Lunsk

Mary Brady

Andrew Greenwood

Celia Maldonado

Roger W. Smith & Sheila Stamper

Arlene R. Bruskin

Kyle Haines

Blase Masini

Teri Burke

Jeanne & Gerry Hall

Joellen McGugan

Steven Chudnick

Sue Hammond

Ashley Mignosi

Erwin & Patricia Cohen

Elizabeth Haughie

Barbara A. Miller

Mary R. Coleman

Joshuah Hernandez

Johanna Miller

Frances Collazo

Maria Hernandez

Paul M. Mills

Michelle & Andrew Dahl

Judy Herriman

Shaw Miseyko

Toby R. Davidow

Judith & Francis J. Higgins

Teresa Myers

Peter De Lijser

Rick Hind

Sharyn A. Novotny

Kevin Degroft

Rosalie Hish

John O’Rourke

Michael DeJoy

Kian Javadi Namin

Jamie Pawelek

Megan Denecour

Ajay Kalra

Daniel Peacock

Victoria Dillon

Susan Kelley

Thomas Peele

Carolyn Dobson

Mary K King

Don Pendergrass

Shannon Dorsey

Lawrence Kirzhner

Linda P. Pepe

Kenneth P. Ducote

Michael Klaessy & Susan Poll Klaessy

Benjamin & Elizabeth A. Pickett

Susana Enriquez

Jeffrey Souter Donna St. George Rod Stoner Danielle Surra Vincent S. Talerico Isaac Thomas Alicia Turner Daniel & Laura Wallenstein Bruce & Sandra Wells Martin White & Nancy J. Trapp Christopher H. Wilder Jennifer Wise Annelle Woggon Richard Zavadowski Maggie Zeqiri Alan Zube

Rebecca A. Pimentel

THE MASON SOCIETY

The Mason Society honors those who support the Lymphoma Research Foundation’s work through bequests or other planned gifts. Planned giving provides an important and long-term funding source that can be used to accelerate biomedical research and the development of new treatments now and in the future.

Susan E. Baer

Jean & Steven Eichberg

Kimberly A. Metcalf

Amy Louise Barnett

Michael Fisher

Maxa Schutzbank Berid

Gregory Gest

Lawrence Prager & Linda Myszak

Carl & Debbie Berkowitz

Tom S. Lakritz

John Cohee

Judith Lender

Carol Davey

Debra & Michael Linick

24

Harris M. Sholman Robert Werner

IN LOVING MEMORY

JERRY FREUNDLICH

In 2023, the Lymphoma Research Foundation (LRF) lost its co-founder and champion, Jerry Freundlich.

As a result of Jerry’s personal journey with non-Hodgkin lymphoma, he and his wife Barbara founded the Foundation, recognizing the significant need to increase investment in lymphoma research and support those personally impacted by a lymphoma diagnosis. Working with the late Dr. Joseph Bertino, the Foundation was created in the Freundlichs’ home and eventually became the largest lymphomaspecific organization in the country, led by an elite Scientific Advisory Board comprised of the world’s leading lymphoma researchers and clinicians. In addition to being its co-founder, Jerry served the organization as President and Chair of the Board, Director, and most recently as a Director Emeritus.

Jerry is remembered as a lymphoma survivor whose generosity and vision have impacted the lives of millions of members of the lymphoma community. The Foundation will continue this life-saving work, always remembering Jerry’s goal to see a world without lymphoma.

To that end, in 2023, LRF established a new scientific initiative aimed at better understanding existing survivorship care recommendations for patients with hematologic malignancies.

This initiative, led by LRF’s Scientific Advisory Board, will include a national workshop series to address these issues and inform the Foundation’s patient support services and education programs.

The highlight of each workshop will be an invited lecture intended to address the most pivotal survivorship issues in the field. The lecturers will be lymphoma and cancer survivorship experts and advocates who share LRF’s mission to eradicate lymphoma and serve all those touched by this disease. The Foundation has named this distinguished lecture series “The Founder’s Lecture” in memory of Jerry Freundlich. LRF could think of no better way to honor Jerry’s legacy than by naming this prestigious and important keynote lecture series in his memory.

COMMIT TO YOUR FUTURE IMPACT TODAY When you include the Lymphoma Research Foundation (LRF) in your estate plan, you are investing in the most promising research that has the greatest potential to dramatically improve the lives of those impacted by lymphoma.

Thank you for ensuring LRF can serve those touched by this disease well into the future and ultimately eradicate lymphoma.

To learn more, contact Lynne Winter at (646) 531-5184 or lwinter@lymphoma.org, or visit lymphoma.org/legacy.

National Headquarters Wall Street Plaza 88 Pine Street, Suite 2400 New York, NY 10005 LRF Helpline (800) 500-9976 helpline@lymphoma.org

LYMPHOMA.ORG